The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF
Launched by WONJU SEVERANCE CHRISTIAN HOSPITAL · Apr 7, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of two different types of heart failure medications: ARNI (Angiotensin Receptor Neprilysin Inhibitors) and ACE inhibitors/ARBs (Angiotensin-Converting Enzyme inhibitors/Angiotensin II Receptor Blockers). The aim is to see which medication works better for patients with heart failure with reduced ejection fraction (HFrEF), a condition where the heart doesn't pump blood as well as it should. By comparing these treatments in real-world settings, the study hopes to identify any unmet needs in patient care and help shape future healthcare policies regarding heart failure treatments in Korea.
To participate in this trial, you need to be diagnosed with heart failure, specifically with certain conditions related to your heart and kidneys. Eligible participants are generally adults aged 65 and older who have been hospitalized for heart failure. If you join the study, you will receive one of the two medications and be monitored for how well it works for you, as well as any side effects. This research is important as it could lead to better treatment options for heart failure patients and help improve their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HF patients were defined as those with "heart failure" according to the disease code in the main code and the sub-code in the claims data.
- • HF patients who were assigned the following KCD-6 disease codes were considered as: "hypertensive heart disease with (congestive) HF" (I11.0), "hypertensive heart and renal disease with (congestive) HF" (I13.0), "hypertensive heart and renal disease with both (congestive) HF and renal failure" (I13.2), and "HF" (I50) including "congestive HF" (I50.0), "LV failure" (I50.1), and "HF and unspecified" (I50.9).
- • HFrEF patients were defined with the following KCD-6 disease codes: "Congestive heart failure with systolic dysfunction"(I5004), "Left ventricular failure"(I501), "Ischaemic cardiomyopathy"(I22.5), "Dilated cardiomyopathy" (I420).
- • Hospitalized heart failure is defined as the HF disease code and admission.
- Exclusion Criteria:
- • Less than 18 years old
- • In case where investigators determine it's inappropriate to be included in the study as per investigators' clinical judgment
About Wonju Severance Christian Hospital
Wonju Severance Christian Hospital is a leading healthcare institution based in South Korea, renowned for its commitment to innovative medical research and high-quality patient care. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical knowledge through rigorous scientific studies and trials across various therapeutic areas. With a multidisciplinary team of experienced researchers and healthcare professionals, Wonju Severance Christian Hospital strives to improve treatment outcomes and enhance the overall health and well-being of patients. Its state-of-the-art facilities and adherence to ethical standards ensure a robust framework for conducting clinical research that meets both local and international regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wonju, Gangwondo, Korea, Republic Of
Patients applied
Trial Officials
Byung Su Yoo, MD,PhD
Principal Investigator
Yonsei Wonju Christian Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials